NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

ANVS

NYSE:ANVSNYSE
8 announcements
Credibility Score65%
Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
Routineunclear

FDA agrees to Annovis Bio’s pooled safety data plan for buntanetap NDA submission.

about 15 hours ago
▼
Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
OverhypedModerate hypeunclear

Annovis Bio’s Phase 3 Alzheimer’s trial receives a second positive safety review from the DSMB.

17 Nov 2026, 13:00 UTC
▼
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
RoutineModerate hypeunclear

This is a leadership update with no actionable investment data or clinical results disclosed.

1 Jul 2026, 12:15 UTC
▼
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Routineunclear

This is a routine, early-stage capital raise with little actionable detail for investors.

19 May 2026, 20:17 UTC
▼
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
OverhypedModerate hypedeteriorating

Annovis is burning cash fast, betting on distant trial milestones with no near-term payoff.

15 May 2026, 11:41 UTC
▼
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
OverhypedModerate hypeunclear

Promising trial headlines, but too little hard data for a confident investment call.

28 Apr 2026, 12:20 UTC
▼